Mayflower

Mayflower Bioventures is a cell and gene therapy (CGT) venture studio established as a joint venture between Mayo Clinic and Hibiscus BioVentures. The company focuses on accelerating the development and commercialization of novel CGT technologies by providing a structured environment for company creation and clinical translation. By leveraging Mayo Clinic's clinical expertise and Hibiscus BioVentures' operational and investment capabilities, Mayflower aims to bridge the gap between academic research and patient care. The studio identifies high-potential technologies, provides seed funding, and offers strategic guidance to launch independent biotech startups. Its primary goal is to advance transformative therapies for patients with unmet medical needs in the rapidly evolving field of regenerative medicine.